BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg. 1998;227:398-404. [PMID: 9527063 DOI: 10.1097/00000658-199803000-00012] [Cited by in Crossref: 102] [Cited by in F6Publishing: 98] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Kitajima T, Tajima Y, Kuroki T, Tsuneoka N, Adachi T, Kanematsu T. Interleukin-6 expression on the biliary epithelia during inflammation-associated biliary carcinogenesis in bilioenterostomized hamsters. J Surg Res 2010;162:54-8. [PMID: 19555978 DOI: 10.1016/j.jss.2009.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus. 2005;18:146-150. [PMID: 16045574 DOI: 10.1111/j.1442-2050.2005.00474.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
3 Gosain R, Anwar S, Miller A, Iyer R, Mukherjee S. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol 2019;10:537-45. [PMID: 31183205 DOI: 10.21037/jgo.2019.01.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Shimizu T, Yokomuro S, Mizuguchi Y, Kawahigashi Y, Arima Y, Taniai N, Mamada Y, Yoshida H, Akimaru K, Tajiri T. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol 2006;12:6316-24. [PMID: 17072955 DOI: 10.3748/wjg.v12.i39.6316] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
5 Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19:353-358. [PMID: 17962206 DOI: 10.1093/annonc/mdm448] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
6 Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7:133-138. [PMID: 10761792 DOI: 10.1007/s10434-000-0133-7] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 5.5] [Reference Citation Analysis]
7 Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol. 2016;22:1335-1347. [PMID: 26819503 DOI: 10.3748/wjg.v22.i4.1335] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
8 Jusakul A, Yongvanit P, Loilome W, Namwat N, Kuver R. Mechanisms of oxysterol-induced carcinogenesis. Lipids Health Dis. 2011;10:44. [PMID: 21388551 DOI: 10.1186/1476-511X-10-44] [Cited by in Crossref: 55] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
9 Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer. 2003;89:338-343. [PMID: 12865927 DOI: 10.1038/sj.bjc.6601039] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 4.9] [Reference Citation Analysis]
10 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:182-90. [PMID: 30324143 DOI: 10.5114/ceh.2018.78122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
11 Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23. [PMID: 11005561 DOI: 10.1007/BF02725342] [Cited by in Crossref: 87] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
12 Gores G. Cholangiocarcinoma: Current concepts and insights. Hepatology 2003;37:961-9. [DOI: 10.1053/jhep.2003.50200] [Cited by in Crossref: 205] [Cited by in F6Publishing: 171] [Article Influence: 11.4] [Reference Citation Analysis]
13 Cheon YK. The role of photodynamic therapy for hilar cholangiocarcinoma. Korean J Intern Med. 2010;25:345-352. [PMID: 21179270 DOI: 10.3904/kjim.2010.25.4.345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
14 Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54:683-689. [PMID: 18661238 DOI: 10.1007/s10620-008-0390-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
15 Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008;14:6458-66. [PMID: 19030196 DOI: 10.3748/wjg.14.6458] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
16 Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y, Mori M. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49:1725-1740. [PMID: 23298711 DOI: 10.1016/j.ejca.2012.12.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
17 Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology. 1999;29:1037-1043. [PMID: 10094943 DOI: 10.1002/hep.510290423] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 4.5] [Reference Citation Analysis]
18 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21. [PMID: 18536057 DOI: 10.1002/hep.22310] [Cited by in Crossref: 470] [Cited by in F6Publishing: 427] [Article Influence: 36.2] [Reference Citation Analysis]
19 Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:46-52. [PMID: 12095927 DOI: 10.1111/j.1749-6632.2002.tb04093.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
20 Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen WH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel) 2020;12:E3404. [PMID: 33212880 DOI: 10.3390/cancers12113404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs 2018;36:1037-43. [PMID: 29785570 DOI: 10.1007/s10637-018-0600-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
22 Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol 2015;89:541-54. [PMID: 25632846 DOI: 10.1007/s00204-015-1461-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
23 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 3.9] [Reference Citation Analysis]
24 Buettner S, van Vugt JL, IJzermans JN, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131-1142. [PMID: 28260927 DOI: 10.2147/ott.s93629] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
25 Frampton G, Ueno Y, Quinn M, McMillin M, Pae HY, Galindo C, Leyva-Illades D, DeMorrow S. The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol 2012;303:G1202-11. [PMID: 23086914 DOI: 10.1152/ajpgi.00104.2012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
26 Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C, Namwat N. Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse. Cancers (Basel) 2021;13:2134. [PMID: 33925189 DOI: 10.3390/cancers13092134] [Reference Citation Analysis]
27 Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011;105:1370-8. [PMID: 21970875 DOI: 10.1038/bjc.2011.376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
28 Ralphs S, Khan SA. The role of the hepatitis viruses in cholangiocarcinoma. J Viral Hepat. 2013;20:297-305. [PMID: 23565610 DOI: 10.1111/jvh.12093] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
29 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol. 2010;2:136-145. [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
30 Yokomuro S, Tsuji H, Lunz JG 3rd, Sakamoto T, Ezure T, Murase N, Demetris AJ. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology. 2000;32:26-35. [PMID: 10869285 DOI: 10.1053/jhep.2000.8535] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 4.5] [Reference Citation Analysis]
31 Akita M, Ajiki T, Matsumoto T, Shinozaki K, Goto T, Asari S, Toyama H, Kido M, Fukumoto T, Ku Y. Preoperative Cholangitis Affects Survival Outcome in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg 2017;21:983-9. [DOI: 10.1007/s11605-017-3388-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Macias RI. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol 2014;2014:828074. [PMID: 27335842 DOI: 10.1155/2014/828074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
33 Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY, Chi CW. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg. 2000;231:552-558. [PMID: 10749617 DOI: 10.1097/00000658-200004000-00015] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 4.5] [Reference Citation Analysis]
34 Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Kim YS, Lee MS, Lee JS, Shim CS. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol. 2007;102:2164-2170. [PMID: 17617204 DOI: 10.1111/j.1572-0241.2007.01403.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
35 Graham B, Curry J, Smyth T, Fazal L, Feltell R, Harada I, Coyle J, Williams B, Reule M, Angove H, Cross DM, Lyons J, Wallis NG, Thompson NT. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci 2012;103:522-7. [PMID: 22181674 DOI: 10.1111/j.1349-7006.2011.02191.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
36 Wu T, Han C, Lunz JG, Michalopoulos G, Shelhamer JH, Demetris AJ. Involvement of 85-kd cytosolic phospholipase A(2) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology. 2002;36:363-373. [PMID: 12143044 DOI: 10.1053/jhep.2002.34743] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
37 Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007;132:384-396. [PMID: 17241887 DOI: 10.1053/j.gastro.2006.10.037] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 9.5] [Reference Citation Analysis]
38 Han BW, Ye H, Wei PP, He B, Han C, Chen ZH, Chen YQ, Wang WT. Global identification and characterization of lncRNAs that control inflammation in malignant cholangiocytes. BMC Genomics 2018;19:735. [PMID: 30305026 DOI: 10.1186/s12864-018-5133-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
39 Safley SA, Villinger F, Jackson EH, Tucker-Burden C, Cohen C, Weber CJ. Interleukin-6 production and secretion by human parathyroids. Clin Exp Immunol 2004;136:145-56. [PMID: 15030526 DOI: 10.1111/j.1365-2249.2004.02419.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
40 Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122:143-159. [PMID: 22029668 DOI: 10.1042/cs20110340] [Cited by in Crossref: 391] [Cited by in F6Publishing: 212] [Article Influence: 39.1] [Reference Citation Analysis]
41 Li YY, Chang JW, Hsieh LL, Yeh KY. Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunol. 2010;265:164-171. [PMID: 20851386 DOI: 10.1016/j.cellimm.2010.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
42 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Yeh KY, Li YY, Hsieh LL, Chen JR, Tang RP. The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan. J Clin Immunol 2010;30:53-9. [PMID: 19728052 DOI: 10.1007/s10875-009-9324-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
44 Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, Demetris AJ. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. Hepatology. 1998;28:1260-1268. [PMID: 9794910 DOI: 10.1002/hep.510280514] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 3.4] [Reference Citation Analysis]
45 Zhu H, Han C, Lu D, Wu T. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol. 2014;184:2828-2839. [PMID: 25239565 DOI: 10.1016/j.ajpath.2014.06.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
46 Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26:125-137. [PMID: 28577718 DOI: 10.1016/j.suronc.2016.12.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
47 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
48 Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005;1755:135-150. [PMID: 15921858 DOI: org/10.1016/j.bbcan.2005.04.002] [Reference Citation Analysis]
49 Huang X, Tang T, Zhang G, Liang T. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Mol Cancer 2021;20:50. [PMID: 33685460 DOI: 10.1186/s12943-021-01342-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
50 Pak K, Kim S, Kim IJ, Kim DU, Kim K, Kim H, Kim SJ. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. Nuklearmedizin 2018;53:26-31. [DOI: 10.3413/nukmed-0566-13-03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
51 Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979-88. [PMID: 28192597 DOI: 10.1002/cncr.30571] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
52 Pinto C, Giordano DM, Maroni L, Marzioni M. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:1270-8. [DOI: 10.1016/j.bbadis.2017.07.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
53 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.3] [Reference Citation Analysis]
54 Mott JL, Gores GJ. Targeting IL-6 in cholangiocarcinoma therapy. Am J Gastroenterol 2007;102:2171-2. [PMID: 17897336 DOI: 10.1111/j.1572-0241.2007.01394.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
55 Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, Periago MV, Bhudhisawasdi V, Yonglitthipagon P, Mulvenna J. Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis. 2012;6:e1654. [PMID: 22629477 DOI: 10.1371/journal.pntd.0001654] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
56 Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005;42:1329-1338. [PMID: 16317687 DOI: 10.1002/hep.20966] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 10.4] [Reference Citation Analysis]
57 Milburn Jessup J. Tumor markers – prognostic and therapeutic implications for colorectal carcinoma. Surgical Oncology 1998;7:139-51. [DOI: 10.1016/s0960-7404(99)00028-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Loosen SH, Benz F, Niedeggen J, Schmeding M, Schüller F, Koch A, Vucur M, Tacke F, Trautwein C, Roderburg C, Neumann UP, Luedde T. Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma. Clin Transl Med 2016;5:39. [PMID: 27709523 DOI: 10.1186/s40169-016-0120-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
59 Nakagawa H, Hayata Y, Yamada T, Kawamura S, Suzuki N, Koike K. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. Int J Mol Sci. 2018;19. [PMID: 29895797 DOI: 10.3390/ijms19061745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
60 Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, Pichler M, Kiesslich T, Mayr C. Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. J Clin Med 2020;9:E1200. [PMID: 32331331 DOI: 10.3390/jcm9041200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006;44:1055-1065. [PMID: 16469407 DOI: 10.1016/j.jhep.2005.10.030] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 5.0] [Reference Citation Analysis]
62 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
63 Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9:29820-29841. [PMID: 30038723 DOI: 10.18632/oncotarget.25661] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 17.3] [Reference Citation Analysis]
64 Wang WT, Ye H, Wei PP, Han BW, He B, Chen ZH, Chen YQ. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol. 2016;9:117. [PMID: 27809873 DOI: 10.1186/s13045-016-0348-0] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 24.2] [Reference Citation Analysis]
65 Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006;44:1055-1065. [PMID: 16469407 DOI: org/10.1016/j.jhep.2005.10.030] [Reference Citation Analysis]
66 Kleinegger F, Hofer E, Wodlej C, Golob-schwarzl N, Birkl-toeglhofer AM, Stallinger A, Petzold J, Orlova A, Krassnig S, Reihs R, Niedrist T, Mangge H, Park YN, Thalhammer M, Aigelsreiter A, Lax S, Garbers C, Fickert P, Rose-john S, Moriggl R, Rinner B, Haybaeck J. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:308-21. [DOI: 10.1016/j.bbadis.2018.11.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
67 Gores GJ. Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J Hepatol 2003;38:671-3. [PMID: 12713880 DOI: 10.1016/s0168-8278(03)00125-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
68 Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:7033-7058. [PMID: 19084911 DOI: 10.3748/wjg.14.7033] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
69 Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol. 2009;70:151-158. [PMID: 19272324 DOI: 10.1016/j.humimm.2009.01.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
70 Skipworth JR, Timms JF, Pereira SP. Novel diagnostic and prognostic biomarkers in biliary tract cancer. Expert Opin Med Diagn 2013;7:487-99. [PMID: 23971898 DOI: 10.1517/17530059.2013.826646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Uchikura K, Takao S, Nakajo A, Miyazono F, Nakashima S, Tokuda K, Matsumoto M, Shinchi H, Natsugoe S, Aikou T. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol 2002;9:364-70. [PMID: 11986188 DOI: 10.1007/BF02573871] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
72 Neumann S, Kaup FJ, Scheulen S. Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours. Comp Clin Path 2012;21:539-44. [PMID: 23049492 DOI: 10.1007/s00580-010-1126-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
73 Cuenco J, Wehnert N, Blyuss O, Kazarian A, Whitwell HJ, Menon U, Dawnay A, Manns MP, Pereira SP, Timms JF. Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget. 2018;9:17430-17442. [PMID: 29707118 DOI: 10.18632/oncotarget.24732] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
74 Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep 2015;5:12122. [PMID: 26161813 DOI: 10.1038/srep12122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
75 Braconi C, Swenson E, Kogure T, Huang N, Patel T. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS One 2010;5:e15195. [PMID: 21179572 DOI: 10.1371/journal.pone.0015195] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
76 Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL. C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006;12:5495-500. [PMID: 17006987 DOI: 10.3748/wjg.v12.i34.5495] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
77 Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer. 2009;12:95-100. [PMID: 19562463 DOI: 10.1007/s10120-009-0509-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 6.1] [Reference Citation Analysis]
78 Allison RR, Zervos E, Sibata CH. Cholangiocarcinoma: An emerging indication for photodynamic therapy. Photodiagnosis and Photodynamic Therapy 2009;6:84-92. [DOI: 10.1016/j.pdpdt.2009.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
79 Lee TY, Cheon YK, Shim CS. Current status of photodynamic therapy for bile duct cancer. Clin Endosc. 2013;46:38-44. [PMID: 23423177 DOI: 10.5946/ce.2013.46.1.38] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
80 Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012;3:463-9. [PMID: 22969912 DOI: 10.3892/etm.2011.424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
81 Ramos-Nino ME. The role of chronic inflammation in obesity-associated cancers. ISRN Oncol. 2013;2013:697521. [PMID: 23819063 DOI: 10.1155/2013/697521] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
82 Marianne O. Photodynamic therapy in the biliary tract. Curr Gastroenterol Rep 2001;3:154-9. [DOI: 10.1007/s11894-001-0013-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Gao J, Xiong R, Xiong D, Zhao W, Zhang S, Yin T, Zhang X, Jiang G, Yin Z. The Adenosine Monophosphate (AMP) Analog, 5-Aminoimidazole-4-Carboxamide Ribonucleotide (AICAR) Inhibits Hepatosteatosis and Liver Tumorigenesis in a High-Fat Diet Murine Model Treated with Diethylnitrosamine (DEN). Med Sci Monit 2018;24:8533-43. [PMID: 30474622 DOI: 10.12659/MSM.910544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
84 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012;1:58-70. [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02] [Cited by in F6Publishing: 60] [Reference Citation Analysis]
85 Wang B, Chen L, Chang HT. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. Biomark Med 2016;10:613-9. [PMID: 27232281 DOI: 10.2217/bmm-2015-0062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
86 Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30:1128-1133. [PMID: 10534331 DOI: 10.1002/hep.510300522] [Cited by in Crossref: 148] [Cited by in F6Publishing: 144] [Article Influence: 6.7] [Reference Citation Analysis]
87 Tsubouchi H. Sustained activation of epidermal growth factor receptor in cholangiocarcinoma: a potent therapeutic target? J Hepatol. 2004;41:859-861. [PMID: 15519661 DOI: 10.1016/j.jhep.2004.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
88 Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236-60. [PMID: 22470194 DOI: 10.18632/oncotarget.466] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 13.7] [Reference Citation Analysis]
89 Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem. 2006;281:24831-24846. [PMID: 16790433 DOI: 10.1074/jbc.m602201200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
90 Viterbo D, Gausman V, Gonda T. Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy. World J Gastrointest Endosc. 2016;8:128-142. [PMID: 26862363 DOI: 10.4253/wjge.v8.i3.128] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
91 Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 2012;106:1583-6. [PMID: 22510747 DOI: 10.1038/bjc.2012.144] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 8.3] [Reference Citation Analysis]
92 Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 2002;51:120-7. [PMID: 12077104 DOI: 10.1136/gut.51.1.120] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 4.2] [Reference Citation Analysis]
93 Asukai K, Kawamoto K, Eguchi H, Konno M, Nishida N, Koseki J, Noguchi K, Hasegawa S, Ogawa H, Yamada D, Tomimaru Y, Tomokuni A, Asaoka T, Noda T, Wada H, Gotoh K, Marubashi S, Nagano H, Doki Y, Mori M, Ishii H. Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1524-31. [PMID: 26228109 DOI: 10.1245/s10434-015-4782-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
94 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 104] [Article Influence: 11.2] [Reference Citation Analysis]
95 Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 2016;122:3657-66. [PMID: 27495988 DOI: 10.1002/cncr.30247] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
96 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 274] [Article Influence: 45.6] [Reference Citation Analysis]
97 Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, Bethony JM, Loukas A. The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol. 2012;28:395-407. [PMID: 22947297 DOI: 10.1016/j.pt.2012.07.006] [Cited by in Crossref: 278] [Cited by in F6Publishing: 218] [Article Influence: 30.9] [Reference Citation Analysis]
98 Saito H, Noji T, Okamura K, Tsuchikawa T, Shichinohe T, Hirano S. A new prognostic scoring system using factors available preoperatively to predict survival after operative resection of perihilar cholangiocarcinoma. Surgery 2016;159:842-51. [DOI: 10.1016/j.surg.2015.10.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]